What does Unicycive Therapeutics, Inc. do?
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients…
What is Unicycive Therapeutics, Inc.'s P/E and P/B ratio?
Unicycive Therapeutics, Inc. has a P/E ratio of -2.3 and a P/B ratio of 2.03.
What is Unicycive Therapeutics, Inc.'s debt-to-equity ratio?
Unicycive Therapeutics, Inc. has a debt-to-equity ratio of 0.01.
How much does Unicycive Therapeutics, Inc. owe compared with what it owns?
Unicycive Therapeutics, Inc. owes $0.26 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Unicycive Therapeutics, Inc.'s Positivity rank?
Unicycive Therapeutics, Inc. is ranked #3,162 of 6,774 companies globally and #1,264 of 4,000 in United States on PositoAI, with a Positivity Score of 20,808.
Does Unicycive Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Unicycive Therapeutics, Inc..
Where can I read the latest news about Unicycive Therapeutics, Inc.?
Recent headlines about Unicycive Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Unicycive Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Unicycive Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.